Navigation Links
Physiology of cardiovascular disease: Gender disparities
Date:9/28/2011

Bethesda, Md. (Sept. 28, 2011) Women generally have a lower risk of developing cardiovascular disease (CVD) than men for most of their adult lives, with lower rates of high blood pressure and a tendency toward higher levels of HDL ("good") cholesterol and lower levels of LDL ("bad") cholesterol. Then comes the great equalizer: menopause. Post-menopausal women develop higher blood pressure at a greater rate than men and their cholesterol levels tend to worsen, even with no significant changes in diet or physical activity. As a result, women's risk of CVD quickly catches up to men's. Yet certain female-only conditions, such as polycystic ovary syndrome (PCOS) and pre-eclampsia, can raise a woman's risk of CVD to a level on par with a man's long before she reaches menopause.

That women's CVD risk increases with conditions that affect their hormonal status suggests that sex hormones play a role in heart health. Experts will explore how both male and female sex hormones affect CVD risk at the Physiology of Cardiovascular Disease: Gender Disparities conference, October 12󈝺 at the University of Mississippi in Jackson. The conference is hosted by the American Physiological Society with additional support from the American Heart Association.

Below is an overview of the meeting, which will coincide with the grand opening of the Women's Health Research Center at the university's medical center.

Thursday, October 13

Symposia I: Aging and CVD
Speakers will cover diabetes and the metabolic syndrome in perimenopausal women, provide an update from the Multi-Ethnic Study of Atherosclerosis trial with respect to early menopause and CVD, and present research on cardiovascular remodeling.

Symposia II: Gender Disparities in Renal Disease
Experts will discuss sex differences in renal injury, podocytes in the urine as an early predictive marker of pre-eclampsia, and the role of androgens in renal disease.

Symposia III: Diabetes, Obesity and Cardiovascular Disease
Researchers will explain the pathophysiology of high blood pressure in obesity and the metabolic syndrome, present research involving the use of pancreatic peptides for the control of glucose homeostasis and appetite, and provide insights into the cardiovascular benefits of exenatide.

Symposia IV: Neuro Mechanisms and Depression in Cardiovascular Disease
Experts will cover the role of sex steroids in baroreflex control and baroreflexes in pregnancy, sex differences in depression and how depression exacerbates CVD, and why men and women respond differently after a stroke.

Friday, October 14

Symposia V: Gender Disparities in Cardiology
With an emphasis on women's needs, speakers will discuss ischemic heart disease, angina, and how pregnancy history predicts CVD in the future with aging.

Symposia VI: Cardiovascular Disease and Inflammation
Researchers will discuss immune mechanisms in CVD, the role of sex hormones in immune system function, and sex differences in inflammatory mediators.

Symposia VII: Gender Differences in Vascular Function
Experts will explain cerebral vascular function in pregnancy and pre-eclampsia, how sex hormones differentially affect endothelial function, and how estrogen signaling affects inflammatory responses.

Symposia VIII: Cardiovascular Disease and Fertility
Speakers will discuss CVD and PCOS, angiotensin 1 receptor autoantibodies in pre-eclampsia, and how angiogenic factors contribute to the hypertension in women with pre-eclampsia.


'/>"/>

Contact: Donna Krupa
dkrupa@the-aps.org
301-634-7209
American Physiological Society
Source:Eurekalert

Related medicine news :

1. MARC Travel Awards announced for the 2010 Integrative Physiology of Exercise Meeting
2. Elsevier introduces Cardiac Electrophysiology Clinics
3. Apex Heart Care, First Arizona Clinic to Install Shape-HF; New Medical Device Measures Patient Physiology to Define Shortness of Breath
4. Rhode Island Hospital researchers find possible cardiovascular risk with NSAID use
5. Erectile Dysfunction May Be Linked With Cardiovascular Trouble
6. How a cardiovascular prevention program in a Brazilian school reduced parents CVD risk
7. The effect of eplerenone vs. placebo on cardiovascular mortality
8. New study calls into question reliance on animal models in cardiovascular research
9. A research tale with a heart to match: Professor looks at cardiovascular disease in dogs
10. Braunwalds Heart Disease: A Textbook of Cardiovascular Medicine comes to the app store
11. Innovations in cardiovascular therapies and treatments will be presented at TCT 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 26, 2016 One of Australia,s ... the formation of a new biotechnology company, Noxopharm Limited [ABN 50 ... an IPO and to list on the ASX. Noxopharm ... ready to enter a Phase 1 clinical study later this year. ... address one of the biggest problems facing cancer patients - the ...
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: